TP-2758(TP-2758) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

S2-7-5-A、TP-038、TP-120

+ [11]

靶点-

作用机制

蛋白质生物合成抑制剂

治疗领域

感染

在研适应症-

非在研适应症

细菌感染

原研机构

Tetraphase Pharmaceuticals (Bermuda) Ltd.

在研机构-

非在研机构

Tetraphase Pharmaceuticals, Inc.

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 TP-2758 相关的临床结果

登录后查看更多信息

100 项与 TP-2758 相关的转化医学

登录后查看更多信息

100 项与 TP-2758 相关的专利（医药）

登录后查看更多信息

2

项与 TP-2758 相关的文献（医药）

2018-02-01·The Journal of antibiotics4区 · 医学

Heterocyclyl tetracyclines. 2. 7-Methoxy-8-pyrrolidinyltetracyclines: discovery of TP-2758, a potent, orally efficacious antimicrobial against Gram-negative pathogens

4区 · 医学

Article

作者: Xiao, Xiao-Yi ; Deng, Yonghong ; Sutcliffe, Joyce A ; Chen, Chi-Li ; Hunt, Diana K ; Sun, Cuixiang ; Grossman, Trudy H ; Clark, Roger B ; Fyfe, Corey

A convergent total synthesis platform led to the discovery of TP-2758 from a series of novel 7-methoxy-8-heterocyclyl tetracycline analogs. TP-2758 demonstrated high in vitro potency against key Gram-negative pathogens including extended spectrum β-lactamases- and carbapenemase-producing Enterobacteriaceae and Acinetobacter spp. strains. This compound was efficacious when administered either intravenously or orally in multiple murine infection models and displayed a favorable preclinical pharmacological profile supporting its advancement into clinical development.

2009-11-01·IDrugs : the investigational drugs journal

Interscience Conference on Antimicrobial Agents and Chemotherapy--49th annual meeting. Part 2. 12-15 September 2009, San Francisco, CA, USA.

Article

作者: Murch, Lisa ; Turner, Ben

The Interscience Conference on Antimicrobial Agents and Chemotherapy held in San Francisco included topics covering new therapeutic developments for the treatment of infectious diseases. This conference report highlights selected presentations on several antibiotics in development including a broad-spectrum penem beta-lactam antibiotic, a novel siderophore monobactam, as well as other novel antibiotics. Investigational drugs discussed include sulopenem and sulopenem etzadroxil (both Pfizer Inc), BAL-30072 (Basilea Pharmaceutica International Ltd), TP-120 and TP-787 (both Tetraphase Pharmaceuticals Inc), NAI-107 (New Anti Infectives Consortium/NexThera Biosciences) and ABI-200 (AdRem Biotech/US Department of Agriculture).

100 项与 TP-2758 相关的药物交易

登录后查看更多信息